Market closedNon-fractional
Cassava Sciences/SAVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cassava Sciences
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Ticker
SAVA
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Austin, United States
Employees
29
Website
www.cassavasciences.com
Cassava Sciences Metrics
BasicAdvanced
$612M
Market cap
-
P/E ratio
-$2.17
EPS
-0.37
Beta
-
Dividend rate
Price and volume
Market cap
$612M
Beta
-0.37
Financial strength
Current ratio
1.738
Quick ratio
1.61
Management effectiveness
Return on assets (TTM)
-33.23%
Return on equity (TTM)
-33.90%
Valuation
Price to book
7.01
Price to tangible book (TTM)
7.02
Price to free cash flow (TTM)
-6.124
Growth
Earnings per share change (TTM)
6.37%
3-year earnings per share growth (CAGR)
94.30%
What the Analysts think about Cassava Sciences
Analyst Ratings
Majority rating from 2 analysts.
Cassava Sciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
$25M
-219.62%
Profit margin
0.00%
NaN%
Cassava Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.63
-$0.61
-$0.50
$0.58
-
Expected
-$0.59
-$0.78
-$0.52
-$0.46
-$0.40
Surprise
6.78%
-21.29%
-3.85%
-226.09%
-
Cassava Sciences News
AllArticlesVideos
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
GlobeNewsWire·1 week ago
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Benzinga·4 weeks ago
Cassava Sciences shares fall after onetime advisor indicted on fraud charges
Market Watch·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cassava Sciences stock?
Cassava Sciences (SAVA) has a market cap of $612M as of July 27, 2024.
What is the P/E ratio for Cassava Sciences stock?
The price to earnings (P/E) ratio for Cassava Sciences (SAVA) stock is 0 as of July 27, 2024.
Does Cassava Sciences stock pay dividends?
No, Cassava Sciences (SAVA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cassava Sciences dividend payment date?
Cassava Sciences (SAVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cassava Sciences?
Cassava Sciences (SAVA) has a beta rating of -0.37. This means that it has an inverse relation to market volatility.
Buy or sell Cassava Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.